ZIOPHARM ONCOLOGY INC overview

Thinking about buying stock in Acer Therapeutics, Ziopharm Oncology, Nutriband, Ocugen, or Flux Power? PR Newswire NEW YORK, Oct. 6, 2021 NEW YORK , Oct. 6, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACER, ZIOP, NTRB, OCGN, and FLUX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ACER:...

Thinking about buying stock in Agrify, Rush Street Interactive, Ocugen, Nine Energy Service, or Ziopharm Oncology? PR Newswire NEW YORK, Oct. 5, 2021 NEW YORK , Oct. 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGFY, RSI, OCGN, NINE, and ZIOP. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. AGFY:...

WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), a sizable and long-term shareholder of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”), today announced that it received the requisite number of written consents to add all three of its director candidates – Robert Postma, Jaime Vieser and Holger Weis – to the Company’s Board of Directors (the “Board”). Although each member of WaterMill’s slate received support...

WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of the outstanding shares of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”), today issued the below letter to shareholders. As a reminder, WaterMill is encouraging shareholders to consent to all of its proposals by voting on the WHITE consent card. We urge...

WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of the outstanding shares of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”), today released a 55-page presentation that details the case for urgent change in the boardroom and summarizes its director candidates’ value-enhancing vision. As a reminder, WaterMill...

White Rock Capital Supports WaterMill's Case for Change at Ziopharm Oncology PR Newswire DALLAS, Nov. 19, 2020 DALLAS , Nov. 19, 2020 /PRNewswire/ -- White Rock Capital Partners, L.P. ("White Rock Capital"), along with all of its related entities, will vote 100% of its approximately 6.1 million common shares (which excludes 3.8 million warrants) of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) ("Ziopharm" or the "Company") in support of WaterMill Asset Management Corp.'s proposal for a reconstituted...

WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of the outstanding shares of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”), today issued the below letter to shareholders in support of the proposals included in its definitive consent statement filed with the U.S. Securities and Exchange Commission on October...

WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of the outstanding shares of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”), today issued the below statement in connection with its filing of a definitive consent statement and accompanying WHITE consent card with the U.S. Securities and Exchange Commission....